However, the presence of myelodysplasia-related mutations in NPM1-mutated/FLT3-ITD-negative patients portended worse outcome, which placed these patients firmly in the 2022 ELN intermediate, not favorable, group. The gene discussed is NPM1; the disease is Myelodysplasia.